Endocrine Abstracts

The prevalence of type 2 diabetes (T2DM) in pregnancy is increasing rapidly worldwide. Most guidelines for diabetes during pregnancy are based on studies in women with type 1 diabetes (T1DM) and as a result, there is an urgent need to improve the knowledge of pregnant women with T2DM. As pregnancy induces insulin resistance in maternal tissues the insulin resistance might be worse in pregnant women with T2DM in the light of the pathophysiology of T2DM, where insulin resistance in itself plays an important role. In addition, pregnant women with T2DM are often older, more obese and show a greater ethnic variation, why pregnant women with T2DM may encounter different challenges during pregnancy, compared to women with T1DM, potentially contributing to a risk of treatment failure, hyperglycemia, and adverse outcomes. The talk will give an overview of cardiometabolic risk factors, co-morbidities, trajectories of glycemic control and insulin resistance in pregnant women with type 2 diabetes both with pre-existing T2DM (P-T2DM) and women with new T2DM (N-T2DM), diagnosed in pregnancy. How these exposures and risk factors affect adverse outcomes for mother and child and how treatment challenges faced by pregnant women with T2DM both before and during pregnancy can be handled will also be addressed.